Iovance Biotherapeutics, Inc. (IOVA)
8.79
+0.09
(+1.03%)
USD |
NASDAQ |
Sep 04, 16:00
8.75
-0.04
(-0.46%)
After-Hours: 20:00
Iovance Biotherapeutics Research and Development Expense (Quarterly) : 58.85M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 58.85M |
| March 31, 2026 | 62.49M |
| December 31, 2025 | 71.20M |
| September 30, 2025 | 75.17M |
| June 30, 2025 | 79.36M |
| March 31, 2025 | 76.88M |
| December 31, 2024 | 72.22M |
| September 30, 2024 | 68.24M |
| June 30, 2024 | 62.08M |
| March 31, 2024 | 79.78M |
| December 31, 2023 | 87.47M |
| September 30, 2023 | 87.53M |
| June 30, 2023 | 86.35M |
| March 31, 2023 | 82.73M |
| December 31, 2022 | 80.57M |
| September 30, 2022 | 72.50M |
| June 30, 2022 | 73.41M |
| March 31, 2022 | 68.30M |
| December 31, 2021 | 75.62M |
| September 30, 2021 | 65.36M |
| June 30, 2021 | 62.12M |
| March 31, 2021 | 55.95M |
| December 31, 2020 | 52.45M |
| September 30, 2020 | 43.05M |
| June 30, 2020 | 49.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 56.95M |
| December 31, 2019 | 54.24M |
| September 30, 2019 | 41.58M |
| June 30, 2019 | 39.30M |
| March 31, 2019 | 30.90M |
| December 31, 2018 | 27.42M |
| September 30, 2018 | 27.95M |
| June 30, 2018 | 24.55M |
| March 31, 2018 | 19.91M |
| December 31, 2017 | 20.70M |
| September 30, 2017 | 17.75M |
| June 30, 2017 | 19.65M |
| March 31, 2017 | 16.62M |
| December 31, 2016 | 10.90M |
| September 30, 2016 | 8.481M |
| June 30, 2016 | 4.463M |
| March 31, 2016 | 4.192M |
| December 31, 2015 | 5.107M |
| September 30, 2015 | 4.983M |
| June 30, 2015 | 4.056M |
| March 31, 2015 | 2.011M |
| December 31, 2014 | 1.687M |
| September 30, 2014 | 0.3539M |
| June 30, 2014 | 0.3612M |
| March 31, 2014 | 0.3027M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen, Inc. | 1.868B |
| AVITA Medical, Inc. | 5.078M |
| Halozyme Therapeutics, Inc. | 27.66M |
| Neurocrine Biosciences, Inc. | 326.70M |
| Editas Medicine, Inc. | 19.76M |